Display options
Cite
Workie MG, Aycheh MW, Birhanu MY, et al. Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia. Patient Prefer Adherence. 2021;15:1143-1151doi: 10.2147/PPA.S307091.
Workie, M. G., Aycheh, M. W., Birhanu, M. Y., & Tsegaye, T. B. (2021). Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia. Patient preference and adherence, 151143-1151. https://doi.org/10.2147/PPA.S307091
Workie, Moges Getie, et al. "Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia." Patient preference and adherence vol. 15 (2021): 1143-1151. doi: https://doi.org/10.2147/PPA.S307091
Workie MG, Aycheh MW, Birhanu MY, Tsegaye TB. Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia. Patient Prefer Adherence. 2021 May 26;15:1143-1151. doi: 10.2147/PPA.S307091. eCollection 2021. PMID: 34079235; PMCID: PMC8165295.
Copy Download .nbib Format: NLM
Share it on

Patient Prefer Adherence. 2021 May 26;15:1143-1151. doi: 10.2147/PPA.S307091. eCollection 2021.

Treatment Interruption Among Drug-Susceptible Pulmonary Tuberculosis Patients in Southern Ethiopia.

Patient preference and adherence

Moges Getie Workie, Moges Wubie Aycheh, Molla Yigzaw Birhanu, Tesfa Birlew Tsegaye

Affiliations

  1. Public Health, Ari Primary Hospital, Gazer, Southern Nations, Nationalities, and Peoples' Region, Ethiopia.
  2. Department of Public Health, College of Health Sciences, Debre Markos University, Debre Markos, Ethiopia.

PMID: 34079235 PMCID: PMC8165295 DOI: 10.2147/PPA.S307091

Abstract

BACKGROUND: Tuberculosis treatment interruption is a failure of attending two scheduled appointments to collect the drugs in either phase of tuberculosis treatment. Even if TB treatment is crucial to achieve a cure and avoid the emergence of drug resistance, treatment interruption is the most testing and deterring factor for successful tuberculosis treatment and one of the problems leading to the development of drug-resistant tuberculosis. TB treatment interruption is the precursor for loss to follow-up and treatment failure, but the magnitude of this problem is unknown in Ethiopia. Thus, this study was intended to identify determinants of treatment interruption among drug-susceptible pulmonary tuberculosis patients in South Ari district, Southern Ethiopia.

METHODS: An institution-based unmatched case control study was conducted from February through April 2020 using 255 samples with a ratio of 2:1 (controls to cases). Data were entered into Epi data version 4.2 and exported for analysis using STATA 14.0 statistical software. The variables having a p-value of less than 0.25 in the bivariable analysis were subjected to multivariable logistic regression analysis. In multivariable logistic regression analysis, AORs, 95% CIs, and p-values of <0.05 were used to identify significant variables.

RESULTS: The median age was 34 (IQR: 18) years in cases and 29 (IQR: 16) years in control groups. Significant factors that were associated with treatment interruption were alcohol consumption (AOR = 2.99, 95% CI; 1.41-6.36); smoking habits (AOR = 2.82, 95% CI; 1.14-6.94); use of traditional medicine (AOR = 2.35, 95% CI 1.05-5.24); co-infected with HIV (AOR=1.58, 95% CI; 1.85-4.29), and waiting time at the health facility ≥30 minutes (AOR = 2.98, 95% CI; 1.31-6.80).

CONCLUSION: Alcohol consumption, waiting time at the health facility ≥30 minutes, smoking habits, used traditional medicine, and HIV co-infected were potential determinants. Enhancing public health education, designing strategies that emphasize patients with HIV co-infection, and reducing waiting times are recommended.

© 2021 Workie et al.

Keywords: directly observed treatment; drug resistant tuberculosis; pulmonary tuberculosis; susceptible; treatment interruption

Conflict of interest statement

The authors reported no conflicts of interest for this work.

References

  1. Pan Afr Med J. 2014 Jan 31;17:78 - PubMed
  2. BMC Med. 2018 Sep 19;16(1):172 - PubMed
  3. Pan Afr Med J. 2017 Nov 06;28(Suppl 1):11 - PubMed
  4. Indian J Med Res. 2012 May;135(5):690-4 - PubMed
  5. PLoS One. 2013 Nov 11;8(11):e78791 - PubMed
  6. Thorax. 2006 Sep;61(9):791-4 - PubMed
  7. BMC Public Health. 2012 Jan 20;12:56 - PubMed
  8. Afr Health Sci. 2015 Jun;15(2):368-77 - PubMed
  9. BMC Public Health. 2018 Apr 2;18(1):422 - PubMed
  10. Int J Infect Dis. 2009 May;13(3):362-8 - PubMed
  11. Ann Clin Microbiol Antimicrob. 2018 Jul 3;17(1):30 - PubMed
  12. BMC Public Health. 2011 Sep 09;11:696 - PubMed
  13. Infect Drug Resist. 2017 Mar 13;10:91-96 - PubMed
  14. PLoS One. 2020 Jun 19;15(6):e0234988 - PubMed
  15. Int J Mycobacteriol. 2016 Sep;5(3):324-327 - PubMed
  16. BMC Public Health. 2013 Aug 28;13:782 - PubMed

Publication Types